Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa-Reference-Cited by-同舟云学术

Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa

Published:2022-08-01 Issue:8 Volume:47 Page:1588-1590
ISSN:1365-2230
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Hunjan Manrup Kaur¹²^ORCID,Bardhan Ajoy¹³^ORCID,Harper Natasha¹,Langman Gerald⁴,Ajayi Bamidele⁵,Suresh Vijay⁵,Heagerty Adrian H. M.¹³⁶^ORCID

Affiliation:

1. Adult Epidermolysis Bullosa Service Solihull Hospital University Hospitals Birmingham NHS Trust Birmingham UK

2. College of Medical and Dental Sciences University of Birmingham Birmingham UK

3. Institute of Clinical Sciences University of Birmingham Birmingham UK

4. Department of Cellular Pathology Queen Elizabeth Hospital University Hospitals Birmingham NHS Trust Birmingham UK

5. Department of Renal Medicine Heartlands and Solihull Hospitals University Hospitals Birmingham NHS Trust Birmingham UK

6. Institute of Ageing and Inflammation University of Birmingham Birmingham UK

Abstract

Abstract We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ced.15228

Reference11 articles.

1. Epidermolysis bullosa;Bardhan;Nat Rev Dis Primers,2020

2. Inherited epidermolysis bullosa and the risk of death from renal disease: experience of the national epidermolysis bullosa registry;Fine;Am J Kidney Dis,2004

3. End-stage renal disease secondary to IgA nephropathy in recessive dystrophic epidermolysis bullosa: a case report;Tammaro;Pediatr Nephrol,2008

4. New strategies and perspectives on managing IgA nephropathy;Selvaskandan;Clin Exp Nephrol,2019

5. Epidermolysis bullosa and the risk of life-threatening cancers: the national EB registry experience, 1986–2006;Fine;J Am Acad Dermatol,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IgA nephropathy in adults with epidermolysis bullosa;Clinical and Experimental Dermatology;2023-05-16

2. Immune abnormalities in IgA nephropathy;Clinical Kidney Journal;2023-02-08